Answers are grounded in this paper and cite their sources.
Background Mepolizumab improves control and reduces clinically significant exacerbations in severe asthma patients. Further research is needed to understand factors influencing patient response. Objective Identify predictors of response to mepolizumab using machine learning techniques. Methods Thirty clinically relevant features from the REALITI-A dataset were analyzed. Response to mepolizumab was defined as change in clinically significant exacerbations at Year 1 post-exposure, being free from clinically significant exacerbations at Year 1, and being free from clinically significant exacerbations at both Year 1 and Year 2 post-exposure for primary, secondary, and exploratory analyses, respectively. Linear/logistic regression, random forest, and XGBoost models were tested. The best-performing model based on R 2 or classification accuracy was used for feature selection. A SHapley Additive exPlanations post-hoc analysis was conducted. Results The primary and secondary analyses included 685 patients; the exploratory analysis included 529 patients. Using XGBoost for the primary analysis, higher pre-exposure clinically significant exacerbations rate, lower body mass index, total immunoglobulin E, lower baseline activity impairment, and lower baseline Asthma Control Questionnaire-5 score were top predictors. For the secondary analysis, the random forest model identified lower pre-exposure clinically significant exacerbations rate, residency outside the United Kingdom, and lower baseline Asthma Control Questionnaire-5 score, body mass index, and baseline activity impairment as top predictors. For the exploratory analysis, XGBoost identified residency outside the United Kingdom, and lower pre-exposure clinically significant exacerbations rate, baseline Asthma Control Questionnaire-5 score, eosinophil levels, and body mass index as top predictors. Conclusion Machine learning models identified key predictors of response to mepolizumab, which could guide clinical decision-making and improve patient outcomes in severe asthma patients.
No takes yet. Share an insight, caveat, or question.
Usuba et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: